Flag of the European Union EU Clinical Trials Register Help

Clinical trials for daily placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,307 result(s) found for: daily placebo. Displaying page 67 of 166.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    EudraCT Number: 2010-020008-31 Sponsor Protocol Number: ACP-103-019 Start Date*: 2013-10-25
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease
    Medical condition: Psychosis associated with Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004064-35 Sponsor Protocol Number: Start Date*: 2018-04-17
    Sponsor Name:Southern Health NHS Foundation Trust
    Full Title: Liraglutide and the management of overweight and obesity in people with schizophrenia: a pilot study
    Medical condition: Schizophrenia, schizoaffective disorder or first episode psychosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002172-40 Sponsor Protocol Number: ISIS426115-CS2 Start Date*: 2014-01-08
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutane...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-002286-40 Sponsor Protocol Number: 1-1 Start Date*: 2006-12-05
    Sponsor Name:Pfizer bv
    Full Title: Chronic Pain Management after Herniorraphy Pregabaline versus Placebo
    Medical condition: Patients suffering from chronic pain of neuropathic character after open hernia repair.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049475 Chronic pain LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004072-19 Sponsor Protocol Number: Acti-INSP-001 Start Date*: 2012-12-28
    Sponsor Name:Vectura GmbH
    Full Title: A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patie...
    Medical condition: Influenza A and B
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003289-29 Sponsor Protocol Number: ACT15102 Start Date*: 2018-06-19
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500 and the Coadministration...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000435-99 Sponsor Protocol Number: 03/06/OXD/TP3 Start Date*: 2006-06-07
    Sponsor Name:Zentiva a.s.
    Full Title: A Randomized, Double Blind, Placebo Controlled Multicenter Study to Assess the Efficacy and Safety of nasal spray ANTIRIN® and NASIC® in the Treatment of Allergic Rhinitis.
    Medical condition: Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-003890-27 Sponsor Protocol Number: 69.52 Start Date*: 2012-09-26
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A multi-centre, double-blind, randomised, parallel group study to assess the efficacy and safety of multiple doses of topically applied hyperemisation-inducing ointment (2 cm ointment line per appl...
    Medical condition: Acute low back pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001524-37 Sponsor Protocol Number: F1J MC HMEF Start Date*: 2005-06-29
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
    Medical condition: Fibromyalgia syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003303-19 Sponsor Protocol Number: RSJ10201 Start Date*: 2019-03-15
    Sponsor Name:Reistone Biopharma Company Limited
    Full Title: A Phase II randomized, placebo controlled, double-blind, 4 arms dose-ranging study to evaluate the efficacy and safety of SHR0302 compared to placebo in patients with moderate to severe active Croh...
    Medical condition: Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000455-16 Sponsor Protocol Number: CYT/Heparin_01/11 Start Date*: 2011-05-05
    Sponsor Name:CYATHUS EXQUIRERE PharmaforschungsGmbH
    Full Title: Efficacy and local tolerability of topically applied heparin (Heparin 2,400 IU/ml Cutaneous Spray) on the suitability of newly constructed primary arteriovenous Fistulas in haemodialysed patients
    Medical condition: This placebo-controlled, randomized and double-blinded pilot study aims to confirm the previous study performed by Stuard et al. (2010) by proving clinically efficacy and local tolerability of topi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004677-27 Sponsor Protocol Number: ABX464-301 Start Date*: 2019-09-16
    Sponsor Name:Abivax
    Full Title: Phase IIa randomized, double blind, placebo controlled, parallel group, multiple dose study on ABX464 in combination with methotrexate (MTX), in patients with moderate to severe active Rheumatoid A...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-004730-18 Sponsor Protocol Number: OSLER_TIMOLOL Start Date*: 2019-12-11
    Sponsor Name:University Hospital Regensburg
    Full Title: The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
    Medical condition: 2) hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000834-36 Sponsor Protocol Number: 43806 Start Date*: 2013-09-26
    Sponsor Name:University Medical Center Utrecht
    Full Title: Simvastatin addition to improve symptoms, cognition and metabolic syndrome in patients with recent-onset schizophrenia.
    Medical condition: Schizophrenia, schizoaffective or schizophreniform disorder (DSM-IV 295.*) or psychosis NOS (not otherwise specified) (298.9)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001891-39 Sponsor Protocol Number: version4.6,29082018 Start Date*: 2018-09-14
    Sponsor Name:XiCoCo study group
    Full Title: Rifaximin-treatment of Collagenous colitis: A prospective, double-blind, placebo-controlled study
    Medical condition: Collagenous Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048928 Colitis collagenous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001654-21 Sponsor Protocol Number: KKS-279 Start Date*: 2020-09-16
    Sponsor Name:Justus-Liebig-University Gießen
    Full Title: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia
    Medical condition: COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003558-98 Sponsor Protocol Number: CHDR1939 Start Date*: 2020-02-10
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, double-blind, placebo-controlled, two way crossover, single centre study evaluating the acute and chronic effect of clonazepam on cognitive tests and patient-reported outcome measures i...
    Medical condition: ARID1B-related intellectual disability
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001184-28 Sponsor Protocol Number: PeP-RALP Start Date*: 2022-10-11
    Sponsor Name:Oslo University Hospital
    Full Title: Perioperative Propranolol in Robotic Assisted Laparoscopic Prostatectomy - A Pilot Study A parallel-group, phase 2, double-blind, 2-arm study to assess the feasibility of conducting a formal large...
    Medical condition: Prostate Cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000732-26 Sponsor Protocol Number: ExPD-ESR-18-13512 Start Date*: 2019-10-23
    Sponsor Name:Stockholm Health Care Services
    Full Title: Effect of Exenatide on disease progression in early Parkinson's disease.
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000163-32 Sponsor Protocol Number: NorPEPS Start Date*: 2017-06-29
    Sponsor Name:Helse-Bergen HF
    Full Title: The Norwegian Prednisolone in Early Psychosis Study - NorPEPS The role of immune-modulating strategies in the treatment of psychosis
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 19 08:14:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA